The Federal Trade Commission (FTC) on September 27, 2024 unexpectedly withdrew from a recently established Memorandum of Understanding (MOU) with ...

Part 1 of this 3-part series for Global Biosimilars Week focuses on legal barriers to biosimilar access in the US, including the patent system, and discusses ongoing legislative efforts to address ...

From drug pricing to reforming the drug regulatory process, Trump’s re-election has plenty of implications for the pharma ...

Boston life sciences and medical device leaders agreed that the change to a Trump administration could create a more ...

As Cigna and Humana pick back up on the potential for a megamerger, executives will be keeping a close eye on the outcomes of ...

“I’m proud that the FTC launched a bipartisan investigation into these shadowy middlemen, and its preliminary findings prove yet again that it’s time to bust up the PBM monopoly.” Eisai ...

This story was originally published by KFF Health News. While customers at Adams Family Pharmacy picked up their ...

Pharmacy Benefit Managers are the middlemen who manage virtually all prescriptions written in the U.S. Serving as brokers among drugmakers, pharmacies, and health insurers, these health care entities ...

Blue Shield of Calif. is bypassing traditional pharmacy benefit managers to bring a Humira-referenced biosimilar, Idacio, to ...

Michael Combs; President, Chief Executive Officer; CorVel Corp. Brandon O'Brien; Chief Financial Officer; CorVel Corp. Presentation. Operator. Thank you for standing ...

It’s the second major investigation into middlemen in the US medicines supply chain, coming after an ongoing FTC probe of pharmacy benefit management (PBM) companies, which started in 2022.